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Thwart Your Destiny; Effect of
Nonacoholic Fatty Liver
Disease Genes on Steatosis,
Liver Injury and Cirrhosis
Varies by Body Mass Index
Most common human diseases develop because of a
combination of endogenous risk combined with expo-
sures. Said another way, these diseases are attributed to
genetic risk combined with environmental triggers.
Nonalcoholic fatty liver disease (NAFLD) is no excep-
tion. There have been both genetic and environmental
variables that have been associated with NAFLD. One
recent article, however, goes beyond these associations
to understand how environmental exposures in the set-
ting of genetic risk variants can exacerbate the develop-
ment of NAFLD.
Genetic associations studies usually assume an addi-
tive genetic model to assess for association with dis-
ease. This translates to a model where having 0, 1, or 2
alleles of a genetic variant increases the risk of the dis-
ease linearly. However, there are situations where those
same alleles instead of increasing risk additively
increase risk multiplicatively. That is, having 0, 1, or 2
alleles increases risk under one set of conditions (body
mass index [BMI] <25 kg/m2) from 1 to 2 to 4 and
another set of conditions (BMI >35 kg/m2) from 1 to
8 to 16 (Fig. 1A). The condition under which the
effects of the same genotype changes is called a modi-
fier. Identifying environmental modifiers of genetic
risk can be done by looking for gene environment
interactions. It is important to identify modifiers of
disease because if the modifier can be changed, the
increased genetic risk for development of disease can
be preferentially and dramatically mitigated.
A recent article by Stender et al.(1) examined the
effect of adiposity on the risk of developing NAFLD
in individuals that carried genetic variants encoding
patatin-like phospholipase domain containing 3
(PNPLA3) p.I148M (isoleucine to methionine at
position 148), TM6SF2 (transmembrane 6 super-
family member 2) p.E167K (glutamic acid to lysine
at position 167), and GCKR (glucokinase regulator)
p.P446L (proline to leucine). Associations of these
variants with hepatic steatosis, nonalcoholic steato-
hepatitis, and fibrosis has been reported in many
cohorts and ancestries.(2-5) This article examined
whether the effects of these variants on development
of NAFLD were modified by BMI. They showed
that as BMI increases from less than 25 kg/m2 to
25-30 kg/m2 to 30-35 kg/m2 and to >35 kg/m2, the
effect of all three genes on hepatic triglyceride con-
tent percent as measured using magnetic resonance
spectroscopy in the Dallas Heart Study also
increased. The difference in hepatic triglyceride per-
cent median increased from 0.98% in the low-risk
PNPLA3-II and PNPLA3-MM, BMI <25 kg/m2
individuals to up to 9.4% in PNPLA3-II and
PNPLA3-MM, BMI >35 kg/m2 individuals (Fig.
1B for PNPLA3). Similar interactions were noted
by another group using visceral adipose tissue and
computed tomography measured fatty liver.(6) They
repeated analyses using alanine aminotransferase
(ALT) as the outcome to test whether it also affected
hepatic injury. They found a significant interaction
for PNPLA3-M with serum ALT levels where the
difference in ALT between PNPLA3-II and
PNPLA3-MM, BMI <25 kg/m2 individuals was
1.0 IU/L up to 7 IU/L between PNPLA3-II and
PNPLA3-MM, BMI >35 kg/m2 individuals in the
Copenhagen Cohort (Fig. 1C). These data corrobo-
rate a similar result reported for PNPLA3-M with
liver function tests in an Italian cohort.(7) Stender
et al. also noted that the difference in odds ratio
(OR) between PNPLA3-II and PNPLA3-MM,
BMI <25 kg/m2 individuals of 1.5-4.8 between
PNPLA3-II and PNPLA3-MM, BMI >35 kg/m2
individuals suggesting an interaction with this liver
disease measure also (Fig. 1D). They observed statis-
tically significant, but smaller, interactions for the
GCKR and TM6SF2 variants in affecting hepatic
triglyceride content, but not with ALT and cirrhosis.
This may be attributed to biology or to low power to
detect an effect for these variants for ALT and
cirrhosis.
Even though the percentage difference in liver fat
and ALT in Stender et al. across obesity groups seems
small, these estimates come from cross-sectional meas-
ures that can sum to larger effects over a lifetime.
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Although BMI is also genetically influenced,(8) it is
modifiable. Therefore, by decreasing the modifier, in
this case BMI, strides may be made toward preventing
common genetic diseases in those genetically suscepti-
ble. From these population-based data, it is estimated
that PNPLA3 MM homozygotes may be able to
reduce their hepatic triglyceride content from 14% to
3%, their ALT from 31 to 18 IU/L and their odds of
developing cirrhosis from 5.8 to 2.5 by reducing their
BMI from >35 to <25 kg/m2. In contrast, PNPLA3
II individuals will only reduce their hepatic triglyceride
content from 4.7% to 1.8% and their ALT from 24 to
11 IU/L by reducing their BMI from >35 to < 25 kg/
m2. The OR for cirrhosis are standardized to 1.0 for
PNPLA3 II individuals, so the comparison is not pos-
sible. Hence, weight loss may be preferentially benefi-
cial for individuals at genetic risk of developing
disease, for example, the ones that carry PNPLA3 M
alleles. By identifying these environmental modifiers of
genetic disease risk, we can better counsel people with
genetic risk of developing human disease to mitigate
all stages of disease from steatosis, to liver injury, to
cirrhosis. Furthermore, because of the mathematical
nature of a gene environment interaction, individuals
at risk can improve their outcome more than individu-
als not at genetic risk of disease by reducing the
modifier.
As proof of concept, two small studies have shown
that individuals with the PNPLA3 NAFLD risk allele
(M) lose more liver fat after weight loss than individu-
als carrying the wild-type allele (I). One set of investi-
gators placed eight PNPLA3 MM homozygotes and
10 PNPLA3 II homozygotes matched by age, sex,
body mass index, and liver fat on a hypocaloric low-
carbohydrate diet for 6 days and measured liver fat
measured by proton magnetic resonance spectroscopy
before and after the diet.(9) Both groups lost, on aver-
age, 3.1 6 0.5 kg of body weight. However liver fat
decreased by 45% in the PNPLA3 MM compared to
18% in the PNPLA3 II group. In a second study, 84
obese individuals were followed after bariatric surgery
for weight loss and for liver fat using magnetic reso-
nance imaging.(10) Individuals that were PNPLA3
MM lost more weight and liver fat 1 year after surgery
compared to PNPLA3 II individuals. These studies
reinforce the idea that decreasing exposure to a disease
modifier can mitigate genetic risk of disease and pro-
vide preferential benefit to individuals at genetic risk of
developing disease. Therefore, genetic risk factors of
disease as well as of environmental variables that can
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FIG. 1. BMI modifies the genetic
effect of PNPLA3 on NAFLD.
(A) Hypothetical effect by geno-
type. (B) Median percent hepatic
triglyceride content percent
(HTGC %) 6 interquartile range
(IQR) by PNPLA3 genotype. (C)
Median alanine amino transferase
(ALT IU/L) 6 IQR by PNPLA3
genotype. (D) Odds of developing
cirrhosis (OR 6 95% confidence
interval) by PNPLA3 genotype in
individuals with BMI <25 kg/m2
and BMI >5 kg/m2. Data for
(B,C,D) from Stender et al.(1)
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modify risk are important to know given that they can
differentially influence the risk versus benefit of inter-
ventions for disease. Future larger clinical trials by
genotype will be needed to confirm the benefits of
weight loss for individuals with genetic risk and can be
used to guide broader precision medicine approaches
to common genetically influenced diseases.
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Of Mice, Rats, and Men:
Small Animal Model of
Hepatitis C Virus Infection
Alexander Graham Bell has been quoted as saying,
“When one door closes, another opens; but we often
look so long and so regretfully upon the closed door
that we do not see the one which has opened for us.”
This quotation is particularly apt when considering
animal models of hepatitis C virus (HCV) infection.
For over 40 years, Pan troglodytes (common chimpan-
zees) served as an exceptionally valuable animal model
for HCV research. As the only species with known
susceptibility to infection, they were essential for discov-
ery of HCV as the cause of non-A, non-B hepatitis,
parsing mechanisms of protective immunity, vaccine
development, and research leading to direct acting anti-
virals (DAAs) that profoundly changed treatment of
chronic hepatitis C (CHC). That door closed in 2013
when the NIH placed new restrictions on chimpanzee
use in biomedical research. Efforts to develop a more
tractable animal model met with partial success. For
instance, expression of human CD81 and occludin in
liver of laboratory mice facilitated HCV entry, but repli-
cation also required ablation of innate immune signaling
pathways.(1) Barriers to spontaneous entry and replica-
tion of HCV have therefore limited studies of pathoge-
nesis and vaccine development in laboratory mice.
New doors in HCV animal modeling may now be
opening. Two recent publications described experi-
mental infection of mice(2) and rats(3) with a hepacivi-
rus isolated from feral Norway rats (Rattus norvegicus)
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